Estimated GFR Decline as a Surrogate End Point for Kidney Failure: A Post Hoc Analysis From the Reduction of End Points in Non–Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan (RENAAL) Study and Irbesartan Diabetic Nephropathy Trial (IDNT)
Lambers Heerspink HJ., Weldegiorgis M., Inker LA., Gansevoort R., Parving H-H., Dwyer JP., Mondal H., Coresh J., Greene T., Levey AS., de Zeeuw D.